Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Recs

1
Player Avatar DrLinks (52.23) Submitted: 7/20/2013 11:26:09 PM : Outperform Start Price: $31.25 MYGN Score: +11.48

Massive Diagnostics Rx Cmpany!

Featured Broker Partners


Advertisement